Your browser doesn't support javascript.
loading
The immunopeptidomic landscape of ovarian carcinomas.
Schuster, Heiko; Peper, Janet K; Bösmüller, Hans-Christian; Röhle, Kevin; Backert, Linus; Bilich, Tatjana; Ney, Britta; Löffler, Markus W; Kowalewski, Daniel J; Trautwein, Nico; Rabsteyn, Armin; Engler, Tobias; Braun, Sabine; Haen, Sebastian P; Walz, Juliane S; Schmid-Horch, Barbara; Brucker, Sara Y; Wallwiener, Diethelm; Kohlbacher, Oliver; Fend, Falko; Rammensee, Hans-Georg; Stevanovic, Stefan; Staebler, Annette; Wagner, Philipp.
Afiliación
  • Schuster H; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Peper JK; Immatics Biotechnologies GmbH, 72076 Tübingen, Germany.
  • Bösmüller HC; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Röhle K; Institute of Pathology, University Hospital of Tübingen, 72076 Tübingen, Germany.
  • Backert L; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Bilich T; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Ney B; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, 72074 Tübingen, Germany.
  • Löffler MW; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Kowalewski DJ; Institute of Pathology, University Hospital of Tübingen, 72076 Tübingen, Germany.
  • Trautwein N; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Rabsteyn A; Department of General, Visceral and Transplant Surgery, University Hospital of Tübingen, 72076 Tübingen, Germany.
  • Engler T; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) partner site Tübingen, 72076 Tübingen, Germany.
  • Braun S; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Haen SP; Immatics Biotechnologies GmbH, 72076 Tübingen, Germany.
  • Walz JS; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Schmid-Horch B; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Brucker SY; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) partner site Tübingen, 72076 Tübingen, Germany.
  • Wallwiener D; Department of Obstetrics and Gynecology, University Hospital of Tübingen, 72076 Tübingen, Germany.
  • Kohlbacher O; Department of Obstetrics and Gynecology, University Hospital of Tübingen, 72076 Tübingen, Germany.
  • Fend F; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Rammensee HG; Department of Hematology and Oncology, University Hospital of Tübingen, 72076 Tübingen, Germany.
  • Stevanovic S; Department of Immunology, Institute of Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  • Staebler A; Department of Hematology and Oncology, University Hospital of Tübingen, 72076 Tübingen, Germany.
  • Wagner P; Department of Clinical and Experimental Transfusion Medicine, University Hospital of Tübingen, 72076 Tübingen, Germany.
Proc Natl Acad Sci U S A ; 114(46): E9942-E9951, 2017 11 14.
Article en En | MEDLINE | ID: mdl-29093164
Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to exhaustively characterize the immunopeptidomic landscape of epithelial ovarian cancers (EOCs). Additional comparative profiling with the immunopeptidome of a variety of benign sources has unveiled a multitude of ovarian cancer antigens (MUC16, MSLN, LGALS1, IDO1, KLK10) to be presented by HLA class I and class II molecules exclusively on ovarian cancer cells. Most strikingly, ligands derived from mucin 16 and mesothelin, a molecular axis of prognostic importance in EOC, are prominent in a majority of patients. Differential gene-expression analysis has allowed us to confirm the relevance of these targets for EOC and further provided important insights into the relationship between gene transcript levels and HLA ligand presentation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Neoplasias Ováricas / Glicoproteínas de Membrana / Presentación de Antígeno Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2017 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Neoplasias Ováricas / Glicoproteínas de Membrana / Presentación de Antígeno Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2017 Tipo del documento: Article País de afiliación: Alemania
...